W

Westside Medical Associates of Los Angeles | Beverly Hills, CA

Research site

(Unclaimed)

Location

99 N. La Cienega Boulevard, Suite 203, Beverly Hills, California, United States of America

Site insights

Top conditions

Top treatments

Gemcabene

ARO-APOC3

Bococizumab

AT-001

PF-06865571

Obicetrapib

Iron

Ranolazine

MK-0616-008

LY3298176

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 23 total trials

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Obicetrapib

Drug: Placebo

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diab...

Active, not recruiting

Diabetic Cardiomyopathies

Drug: AT-001

Drug: Placebo

Study of ARO-APOC3 in Adults With Dyslipidemia

This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded...

Active, not recruiting

Dyslipidemias

Drug: ARO-APOC3